Consortium studies genetic markers, hopes to predict SJS
The International Serious Adverse Events Consortium (SAEC) is a global, nonprofit partnership between leading pharmaceutical companies, the FDA and academic institutions. It was organized just more than a year ago. Among its goals, the consortium hopes to identify genetic markers that predict which individuals are at risk for drug-related serious adverse reactions, also known as SAEs.
